Literature DB >> 1902292

Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior.

H N Keer1, F D Gaylis, J M Kozlowski, H C Kwaan, K D Bauer, A A Sinha, M J Wilson.   

Abstract

Plasminogen activators (PA), particularly the lower Mr urokinase (u-PA) type, have been associated with tumor cell invasion and metastasis. We have examined the expression of PA by two human prostate cancer cell lines (PC-3 and DU-145) using functional and immunologic techniques. The culture media and cell extracts of the more aggressive PC-3 cell line contained more than two-fold greater PA activity than the relatively indolent DU-145 cell line. Zymographic studies identified the PA expressed as u-PA. PC-3 cells expressed an additional lower molecular weight form of u-PA not noted in DU-145 cells. Heterogeneity in u-PA expression was shown by the fibrin lysis assay, immunohistochemistry, and dual parameter flow cytometry indicating the presence of phenotypically divergent cell populations. Increased u-PA expression may identify those tumor cells that possess aggressive biological potential.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1902292     DOI: 10.1002/pros.2990180303

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  11 in total

1.  Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer.

Authors:  Jean-Sébastien Annicotte; Irena Iankova; Stéphanie Miard; Vanessa Fritz; David Sarruf; Anna Abella; Marie-Laurence Berthe; Danièle Noël; Arnaud Pillon; François Iborra; Pierre Dubus; Thierry Maudelonde; Stéphane Culine; Lluis Fajas
Journal:  Mol Cell Biol       Date:  2006-10       Impact factor: 4.272

2.  Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.

Authors:  G A Soff; J Sanderowitz; S Gately; E Verrusio; I Weiss; S Brem; H C Kwaan
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

3.  RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.

Authors:  Sai MuraliKrishna Pulukuri; Christopher S Gondi; Sajani S Lakka; Aman Jutla; Norman Estes; Meena Gujrati; Jasti S Rao
Journal:  J Biol Chem       Date:  2005-08-26       Impact factor: 5.157

4.  HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I Study.

Authors:  Takuya Osada; Erika J Crosby; Kensuke Kaneko; Joshua C Snyder; Joshua D Ginzel; Chaitanya R Acharya; Xiao-Yi Yang; Thomas J Polascik; Ivan Spasojevic; Rendon C Nelson; Amy Hobeika; Zachary C Hartman; Leonard M Neckers; Andre Rogatko; Philip F Hughes; Jiaoti Huang; Michael A Morse; Timothy Haystead; H Kim Lyerly
Journal:  Mol Cancer Ther       Date:  2021-10-21       Impact factor: 6.261

5.  Anticancer activity of a sub-fraction of dichloromethane extract of Strobilanthes crispus on human breast and prostate cancer cells in vitro.

Authors:  Nik Soriani Yaacob; Nurraihana Hamzah; Nik Nursyazni Nik Mohamed Kamal; Siti Amalina Zainal Abidin; Choon Sheen Lai; Visweswaran Navaratnam; Mohd Nor Norazmi
Journal:  BMC Complement Altern Med       Date:  2010-08-05       Impact factor: 3.659

6.  Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer.

Authors:  Sai Murali Krishna Pulukuri; Norman Estes; Jitendra Patel; Jasti S Rao
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

Review 7.  The plasminogen-plasmin system in malignancy.

Authors:  H C Kwaan
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

8.  DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells.

Authors:  Samia B Bachmann; Sandra C Frommel; Rosalba Camicia; Hans C Winkler; Raffaella Santoro; Paul O Hassa
Journal:  Mol Cancer       Date:  2014-05-27       Impact factor: 27.401

9.  SFMBT2 (Scm-like with four mbt domains 2) negatively regulates cell migration and invasion in prostate cancer cells.

Authors:  Jungsug Gwak; Jee Yoon Shin; Kwanghyun Lee; Soon Ki Hong; Sangtaek Oh; Sung-Ho Goh; Won Sun Kim; Bong Gun Ju
Journal:  Oncotarget       Date:  2016-07-26

10.  The role of AP-1 in self-sufficient proliferation and migration of cancer cells and its potential impact on an autocrine/paracrine loop.

Authors:  Sherif Abd El-Fattah Ibrahim; Aierken Abudu; Eugenia Johnson; Neelum Aftab; Susan Conrad; Michele Fluck
Journal:  Oncotarget       Date:  2018-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.